Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26927562 | 0.94 | MAPT (0.63) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL337736 | 0.88 | TDP1 (0.70) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL19452424 | 0.86 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL2222140 | 0.86 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17223648 | 0.84 | HDAC1 (0.64) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL8937113 | 0.82 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL162806 | 0.82 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL6371649 | 0.82 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL28770542 | 0.82 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL1418881 | 0.82 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0280285-A2 | Process for making and isolating (R)-2-hydroxy 4-phenylbutyric acid and esters | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-31 | — | — | EP | claimed |
| US-10633329-B2 | Method for preparing lisinopril intermediate | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-28 | — | — | US | disclosed |
| CN-110283799-A | Aldehyde ketone reductase BsAKR (YvgN) and its mutant and application | 沈阳药科大学 | 2019-09-27 | — | — | CN | disclosed |
| EP-3543225-A1 | METHOD FOR PREPARING LISINOPRIL INTERMEDIATE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018090963-A1 | METHOD FOR PREPARING LISINOPRIL INTERMEDIATE | 浙江华海药业股份有限公司 | 2018-05-24 | — | — | WO | disclosed |
| WO-2011159177-A1 | IMPROVED AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2011-12-22 | — | — | WO | disclosed |
| EP-0892780-A1 | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| EP-0821675-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1997030971-A1 | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1996033176-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5231084-A | ACE inhibitor | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-27 | — | — | US | disclosed |
| EP-0280285-A2 | Process for making and isolating (R)-2-hydroxy 4-phenylbutyric acid and esters | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633329-B2 | Method for preparing lisinopril intermediate | PKLR, PHYKPL, ACE | HDAC1 276/4885HDAC3 271/4885HDAC2 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.